• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Alimera Sciences launches first product

Article

Atlanta -Start-up ophthalmic pharmaceutical developer Alimera Sciences Inc. has launched its first product, a multi-dose, emollient-based artificial tear drop.

Atlanta-Start-up ophthalmic pharmaceutical developer Alimera Sciences Inc. has launched its first product, a multi-dose, emollient-based artificial tear drop.

Soothe Emollient Eye Drops includes an advanced lipid restorative called Restoryl, designed to re-establish the eye's lipid layer to reduce tear evaporation for up to 8 hours.

Alimera Sciences licensed Soothe in November 2003 from Ocular Research of Boston, a group of eye-care specialists who focus on dry-eye research.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.